Impax Laboratories (IPXL) 39.51 $IPXL
Can Radius Health (RDUS) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:06AM CST
Radius Health, Inc. (RDUS) is expected to report its fourth-quarter and full-year 2014 results on Feb 16 and carries an Earnings ESP of +5.00%.
RDUS: 50.37 (+0.63), IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45)
Alaska AG investigating Impax Labs over possible pay-to-delay deals
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 4:33PM CST
IPXL: 39.51 (+0.69), ENDP: 84.01 (+1.12), PFE: 34.64 (-0.23), SHPG: 239.82 (+6.11)
Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:23PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) announced that the company and its partner R-Tech Ueno, Ltd have entered into a stipulation and license agreement with Par Pharmaceutical, Inc.
IPXL: 39.51 (+0.69), LCI: 57.78 (-0.91), BIIB: 391.66 (-0.45), SCMP: 15.32 (+0.04)
Will Nielsen's (NLSN) Earnings Surprise Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:21AM CST
Nielsen Holdings N.V. (NLSN) is set to report fourth-quarter 2014 results on Feb 12.
IPXL: 39.51 (+0.69), NLSN: 45.59 (+2.02), TSRA: 39.27 (-0.05), ALE: 53.65 (-1.17)
Actavis to Divest U.S. Rights of Doryx to Mayne Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:41PM CST
Actavis (ACT) to divest U.S. rights of Doryx brand to Mayne Pharma, to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Uptrend Call Working As Impax Laboratories Stock Rises 12.0% (IPXL)
Comtex SmarTrend(R) - Tue Feb 10, 9:18AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on January 8th, 2015 at $35.04. In approximately 1 month, Impax Laboratories has returned 12.03% as of today's recent price of $39.26.
IPXL: 39.51 (+0.69)
These 5 Tech Stocks Are Bolting Ahead Of The Market
at Investor's Business Daily - Mon Feb 09, 6:45PM CST
Today's Screen Of The Day is Bolting RS Lines, which includes top-rated companies -- such as Silicon Motion Technology (SIMO) -- whose stocks are outperforming the general market. The Relative Strength (RS) line compares a stock's price action...
IPXL: 39.51 (+0.69), LNKD: 269.00 (+1.83), FB: 75.74 (-0.49), CRUS: 29.36 (+0.01), AAPL: 127.08 (+0.62), SIMO: 29.08 (-0.39), IPGP: 87.26 (+0.07)
What's in Store for Applied Materials (AMAT) this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:50AM CST
Applied Materials, Inc. (AMAT) is set to report fiscal first-quarter 2015 results on Feb 11.
IPXL: 39.51 (+0.69), AMAT: 24.12 (-0.02), CYS: 8.78 (+0.04), ACGL: 59.95 (+0.36)
Will Cisco Systems (CSCO) Q2 Earnings Surprise Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:40AM CST
Cisco Systems (CSCO) is set to report second-quarter fiscal 2015 results on Feb 11.
IPXL: 39.51 (+0.69), CYS: 8.78 (+0.04), ACGL: 59.95 (+0.36), CSCO: 29.43 (-0.03)
Actavis to Divest Respiratory Business to AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 3:15PM CST
Actavis (ACT) to divest rights of its branded respiratory business to AstraZeneca (AZN), to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
Pfizer Set to Acquire Hospira for $17B, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 2:44PM CST
Pfizer (PFE) is set to acquire Hospira (HSP) in an all-cash transaction valued at about $17 billion or $90 per share which will strengthen its Global Established Pharmaceutical business.
IPXL: 39.51 (+0.69), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), HSP: 87.35 (unch)
Research and Markets: Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
Business Wire - Fri Feb 06, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/7pz7ds/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering.
IPXL: 39.51 (+0.69), GSK: 47.94 (+1.99)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
Teva Beats on Q4 Earnings By a Penny, Maintains Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Feb 06, 8:01AM CST
Teva (TEVA) expects to earn $5.00 - $5.30 per share on revenues of $19 - $19.4 billion in 2015.
IPXL: 39.51 (+0.69), BIIB: 391.66 (-0.45), TEVA: 56.77 (-0.58), AMAG: 41.49 (+0.23)
Pfizer Xeljanz Label Expansion Application Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:13PM CST
Pfizer's (PFE) Xeljanz is under review in the U.S. for the treatment of adult patients suffering from moderate-to-severe chronic plaque psoriasis.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), PFE: 34.64 (-0.23), NVS: 102.20 (-0.17)
Pfizer's Breast Cancer Drug Ibrance Wins Early FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 11:30AM CST
Pfizer's (PFE) breast cancer drug, Ibrance, gained accelerated approval for the treatment of postmenopausal women suffering from advanced breast cancer.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), PFE: 34.64 (-0.23), NVS: 102.20 (-0.17)
Mylan, Theravance Ink Deal to Develop, Market COPD Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 5:03PM CST
Mylan Inc. (MYL) and Theravance will collaborate for the development of TD-4208 for COPD and other respiratory diseases and its commercialization (upon FDA approval).
IPXL: 39.51 (+0.69), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), TBPH: 18.51 (+0.28)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Roche's Anti-PDL1 Gets Breakthrough Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 4:37PM CST
Roche's (RHHBY) MPDL3280A received Breakthrough Therapy designation from the FDA for the treatment of PD-L1 positive non-small cell lung cancer (NSCLC).
IPXL: 39.51 (+0.69), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58)
Can Radius Health (RDUS) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:06AM CST
Radius Health, Inc. (RDUS) is expected to report its fourth-quarter and full-year 2014 results on Feb 16 and carries an Earnings ESP of +5.00%.
RDUS: 50.37 (+0.63), IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45)
Alaska AG investigating Impax Labs over possible pay-to-delay deals
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 4:33PM CST
IPXL: 39.51 (+0.69), ENDP: 84.01 (+1.12), PFE: 34.64 (-0.23), SHPG: 239.82 (+6.11)
Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:23PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) announced that the company and its partner R-Tech Ueno, Ltd have entered into a stipulation and license agreement with Par Pharmaceutical, Inc.
IPXL: 39.51 (+0.69), LCI: 57.78 (-0.91), BIIB: 391.66 (-0.45), SCMP: 15.32 (+0.04)
Will Nielsen's (NLSN) Earnings Surprise Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:21AM CST
Nielsen Holdings N.V. (NLSN) is set to report fourth-quarter 2014 results on Feb 12.
IPXL: 39.51 (+0.69), NLSN: 45.59 (+2.02), TSRA: 39.27 (-0.05), ALE: 53.65 (-1.17)
Actavis to Divest U.S. Rights of Doryx to Mayne Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:41PM CST
Actavis (ACT) to divest U.S. rights of Doryx brand to Mayne Pharma, to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Uptrend Call Working As Impax Laboratories Stock Rises 12.0% (IPXL)
Comtex SmarTrend(R) - Tue Feb 10, 9:18AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on January 8th, 2015 at $35.04. In approximately 1 month, Impax Laboratories has returned 12.03% as of today's recent price of $39.26.
IPXL: 39.51 (+0.69)
These 5 Tech Stocks Are Bolting Ahead Of The Market
at Investor's Business Daily - Mon Feb 09, 6:45PM CST
Today's Screen Of The Day is Bolting RS Lines, which includes top-rated companies -- such as Silicon Motion Technology (SIMO) -- whose stocks are outperforming the general market. The Relative Strength (RS) line compares a stock's price action...
IPXL: 39.51 (+0.69), LNKD: 269.00 (+1.83), FB: 75.74 (-0.49), CRUS: 29.36 (+0.01), AAPL: 127.08 (+0.62), SIMO: 29.08 (-0.39), IPGP: 87.26 (+0.07)
What's in Store for Applied Materials (AMAT) this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:50AM CST
Applied Materials, Inc. (AMAT) is set to report fiscal first-quarter 2015 results on Feb 11.
IPXL: 39.51 (+0.69), AMAT: 24.12 (-0.02), CYS: 8.78 (+0.04), ACGL: 59.95 (+0.36)
Will Cisco Systems (CSCO) Q2 Earnings Surprise Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:40AM CST
Cisco Systems (CSCO) is set to report second-quarter fiscal 2015 results on Feb 11.
IPXL: 39.51 (+0.69), CYS: 8.78 (+0.04), ACGL: 59.95 (+0.36), CSCO: 29.43 (-0.03)
Actavis to Divest Respiratory Business to AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 3:15PM CST
Actavis (ACT) to divest rights of its branded respiratory business to AstraZeneca (AZN), to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
Pfizer Set to Acquire Hospira for $17B, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 2:44PM CST
Pfizer (PFE) is set to acquire Hospira (HSP) in an all-cash transaction valued at about $17 billion or $90 per share which will strengthen its Global Established Pharmaceutical business.
IPXL: 39.51 (+0.69), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), HSP: 87.35 (unch)
Research and Markets: Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
Business Wire - Fri Feb 06, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/7pz7ds/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering.
IPXL: 39.51 (+0.69), GSK: 47.94 (+1.99)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
Teva Beats on Q4 Earnings By a Penny, Maintains Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Feb 06, 8:01AM CST
Teva (TEVA) expects to earn $5.00 - $5.30 per share on revenues of $19 - $19.4 billion in 2015.
IPXL: 39.51 (+0.69), BIIB: 391.66 (-0.45), TEVA: 56.77 (-0.58), AMAG: 41.49 (+0.23)
Pfizer Xeljanz Label Expansion Application Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:13PM CST
Pfizer's (PFE) Xeljanz is under review in the U.S. for the treatment of adult patients suffering from moderate-to-severe chronic plaque psoriasis.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), PFE: 34.64 (-0.23), NVS: 102.20 (-0.17)
Pfizer's Breast Cancer Drug Ibrance Wins Early FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 11:30AM CST
Pfizer's (PFE) breast cancer drug, Ibrance, gained accelerated approval for the treatment of postmenopausal women suffering from advanced breast cancer.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), PFE: 34.64 (-0.23), NVS: 102.20 (-0.17)
Mylan, Theravance Ink Deal to Develop, Market COPD Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 5:03PM CST
Mylan Inc. (MYL) and Theravance will collaborate for the development of TD-4208 for COPD and other respiratory diseases and its commercialization (upon FDA approval).
IPXL: 39.51 (+0.69), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), TBPH: 18.51 (+0.28)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Roche's Anti-PDL1 Gets Breakthrough Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 4:37PM CST
Roche's (RHHBY) MPDL3280A received Breakthrough Therapy designation from the FDA for the treatment of PD-L1 positive non-small cell lung cancer (NSCLC).
IPXL: 39.51 (+0.69), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58)
